NYSE:WAT - Waters Stock Price, News, & Analysis

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters declared that its Board of Directors has approved a share buyback program on Tuesday, April 24th 2018, which authorizes the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 18.2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board of directors believes its shares are undervalued.

Waters Co. (NYSE:WAT) announced its quarterly earnings results on Tuesday, October, 23rd. The medical instruments supplier reported $1.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.90 by $0.02. The medical instruments supplier earned $578.02 million during the quarter, compared to the consensus estimate of $587.43 million. Waters had a return on equity of 30.68% and a net margin of 2.32%. The company's revenue for the quarter was up 2.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.77 EPS. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, January 22nd 2019. View Earnings Estimates for Waters.

Waters updated its fourth quarter earnings guidance on Tuesday, October, 23rd. The company provided earnings per share guidance of $2.55-2.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.69. Waters also updated its FY 2018 guidance to $8.00-8.10 EPS.

15 Wall Street analysts have issued 12 month price objectives for Waters' stock. Their predictions range from $185.00 to $230.00. On average, they expect Waters' stock price to reach $206.0769 in the next twelve months. This suggests a possible upside of 3.3% from the stock's current price. View Analyst Price Targets for Waters.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 1 sell rating, 11 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Waters.

Media headlines about WAT stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Waters earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the company's share price in the next several days.

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT) and Harvard Bioscience (HBIO).

Waters' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.41%), Massachusetts Financial Services Co. MA (5.96%), Bank of New York Mellon Corp (6.00%), Baillie Gifford & Co. (3.39%), Janus Henderson Group PLC (2.76%) and Veritas Asset Management LLP (2.14%). Company insiders that own Waters stock include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Nomura Asset Management Co. Ltd., Massachusetts Financial Services Co. MA, Acadian Asset Management LLC, Smith Asset Management Group LP, Wells Fargo & Company MN, Renaissance Technologies LLC and Mackenzie Financial Corp. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters.

WAT stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Select Equity Group L.P., Nordea Investment Management AB, Man Group plc, AQR Capital Management LLC, Commonwealth Bank of Australia, Nuance Investments LLC and Jefferies Group LLC. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $199.57.

Waters has a market capitalization of $14.79 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

The official website for Waters is http://www.waters.com.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]